Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TALC vs SOTRADECOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
Intrapleural administration: 5 g mixed with 250 m L normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
Not applicable; talc is a non-absorbable material. No systemic half-life exists; local persistence in pleural space can be months to years.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Not metabolized; inert substance. Cleared by lymphatic drainage and phagocytosis by macrophages.
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Talc is not absorbed systemically; elimination is primarily via fecal excretion of the unabsorbed material. In cases of pleural administration, talc particles are cleared by lymphatic drainage and may be phagocytized by macrophages; no significant renal or biliary excretion occurs.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Not applicable; talc does not bind to plasma proteins as it is not systemically absorbed.
>90% bound to plasma proteins, primarily albumin
Not applicable; talc remains at site of administration (pleural space, lungs) or in GI tract; no systemic distribution.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Oral: negligible (<0.1%); inhalation: minimal systemic absorption; intrapleural: not systemically available.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
No dose adjustment required; talc is not significantly renally eliminated.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
No dose adjustment required.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
Not established; safety and efficacy in children have not been determined.
Safety and efficacy not established in pediatric patients (age <18 years).
No specific dose adjustment; use with caution due to potential comorbidities and reduced pulmonary reserve.
No specific dose adjustment required; consider comorbidities and overall health status.
None
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
Risk of acute respiratory distress syndrome (ARDS) and pneumonitis due to systemic absorption,Hypersensitivity reactions including anaphylaxis,Fever and chest pain common post-procedure,Do not use in patients with extensive pleural fibrosis or trapped lung
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Hypersensitivity to talc,Uncontrolled infection at the site of administration,Bronchopleural fistula,Pregnancy (relative)
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
No known food interactions with intrapleural talc administration.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
Talc is not absorbed systemically; topical use considered safe during breastfeeding. No M/P ratio available as systemic levels are negligible.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
No dose adjustment required for topical or perineal use; systemic levels negligible.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
Talc is used for pleurodesis in malignant pleural effusions. Administer as intrapleural slurry via chest tube; premedicate with lidocaine to reduce pain. Monitor for fever, chest pain, and respiratory distress. Contraindicated in patients with known talc sensitivity or active infection.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
Talc is used to prevent fluid buildup in the chest cavity by causing the lung to stick to the chest wall.,You may experience chest pain, fever, or shortness of breath after the procedure.,Report any worsening pain, difficulty breathing, or signs of infection such as chills or fever.,This procedure is not a cure for the underlying cancer but helps manage symptoms.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TALC vs SOTRADECOL, answered by our medical review team.
TALC is a Sclerosing agent that works by Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.. SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TALC and SOTRADECOL depend on the specific clinical indication. These are both Sclerosing agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TALC is: Intrapleural administration: 5 g mixed with 250 m L normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.. The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TALC and SOTRADECOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TALC is classified as Category C. No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester.. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.